UB 311

Drug Profile

UB 311

Alternative Names: Alzheimer's disease vaccine - United Biomedical; Amyloid-beta-1-14-vaccine; UB311; UBITh AD immunotherapeutic vaccine (UB 311) - United Biomedical

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator United Biomedical
  • Class Alzheimer vaccines; Antidementias; Peptide vaccines; Vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 23 May 2017 Adverse events data from a phase I trial in Alzheimer's disease released by United Neuroscience
  • 23 May 2017 United Neuroscience completes enrolment in its phase II trial for Alzheimer's disease in Taiwan (NCT02551809)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top